Cargando…

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma

Central nervous system (CNS) relapse is an infrequent but severe complication for DLBCL patients, associated with poor prognosis. Intravenous prophylaxis with high-dose methotrexate has shown promising results but is rarely feasible in elderly and/or nephropathic patients. A 83 years old woman with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cencini, Emanuele, Fabbri, Alberto, Arrigucci, Umberto, Cerase, Alfonso, Bocchia, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2017
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499499/ https://www.ncbi.nlm.nih.gov/pubmed/28698783 http://dx.doi.org/10.4084/MJHID.2017.040

Ejemplares similares

Primary CNS lymphoma: latest updates and a 10-year monocenter experience
por: Cencini, Emanuele, et al.
Publicado: (2018)

Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas
por: Cencini, Emanuele, et al.
Publicado: (2021)

Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
por: Gozzetti, Alessandro, et al.
Publicado: (2012)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

The Role of Tumor-Associated Macrophages in Hematologic Malignancies
por: Cencini, Emanuele, et al.
Publicado: (2021)

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
por: Cencini, Emanuele, et al.
Publicado: (2021)

Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
por: Al Dhafiri, Mahdi, et al.
Publicado: (2019)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Lenalidomide in Diffuse Large B-Cell Lymphoma
por: Thieblemont, Catherine, et al.
Publicado: (2012)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
por: Cencini, Emanuele, et al.
Publicado: (2023)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma
por: Pillar, Nir, et al.
Publicado: (2017)

CNS relapse of diffuse large B cell Lymphoma A single centre experience
por: Nazir, Adil, et al.
Publicado: (2017)

Lenalidomide in Combination with Dexamethasone in Elderly Patients with Advanced, Relapsed or Refractory Multiple Myeloma and Renal Failure
por: Tosi, Patrizia, et al.
Publicado: (2013)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
por: Min Byun, Ja, et al.
Publicado: (2023)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Relapse pattern and prognosis of primary CNS lymphoma
por: Dahiya, Saurabh, et al.
Publicado: (2012)

Characteristics of Primary Cutaneous Lymphoma in Italy: A Tertiary Care, Single-Center Study
por: D’Onghia, Martina, et al.
Publicado: (2023)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

Multiply Relapsed Secondary CNS Non-Germinal Center Diffuse Large B-Cell Lymphoma Successfully Treated with CNS-Centric Therapy
por: Fournier, Lyndsey L, et al.
Publicado: (2023)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2021)

Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma
por: Khorasanchi, Adam, et al.
Publicado: (2022)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2022)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature
por: Vergori, Alessandra, et al.
Publicado: (2015)

Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective cohort in China
por: Wang, Yawen, et al.
Publicado: (2022)

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
por: Bobillo, Sabela, et al.
Publicado: (2021)

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
por: Pirosa, Maria Cristina, et al.
Publicado: (2022)

Relapse pattern and prognostic factors for patients with primary CNS lymphoma
por: Suh, Cheolwon, et al.
Publicado: (2012)

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
por: Dührsen, Ulrich, et al.
Publicado: (2021)

Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma
por: Perrone, Gabriele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hohc2m1l37pn4807fqq7ibvic4